Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 64
Filtrar
Más filtros

País/Región como asunto
País de afiliación
Intervalo de año de publicación
1.
Mem Inst Oswaldo Cruz ; 117: e210172, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35674528

RESUMEN

In this chapter, the main prognostic markers of Chagas heart disease are addressed, with an emphasis on the most recent findings and questions, establishing the basis for a broad discussion of recommendations and new approaches to managing Chagas cardiopathy. The main biological and genetic markers and the contribution of the electrocardiogram, echocardiogram and cardiac magnetic resonance are presented. We also discuss the most recent therapeutic proposals for heart failure, thromboembolism and arrhythmias, as well as current experience in heart transplantation in patients suffering from severe Chagas cardiomyopathy. The clinical and epidemiological challenges introduced by acute Chagas disease due to oral contamination are discussed. In addition, we highlight the importance of ageing and comorbidities in influencing the outcome of chronic Chagas heart disease. Finally, we discuss the importance of public policies, the vital role of funding agencies, universities, the scientific community and health professionals, and the application of new technologies in finding solutions for better management of Chagas heart disease.


Asunto(s)
Cardiomiopatía Chagásica , Enfermedad de Chagas , Trasplante de Corazón , Cardiomiopatía Chagásica/diagnóstico , Enfermedad Crónica , Corazón , Humanos , Infección Persistente , Pronóstico
2.
Clin Infect Dis ; 72(6): 1084-1092, 2021 03 15.
Artículo en Inglés | MEDLINE | ID: mdl-32772104

RESUMEN

Orally-transmitted acute Chagas disease (CD) is emerging as an important public health problem. The prognosis of acute infection following oral transmission is unknown. The aim of this study was to analyze and summarize data on orally-transmitted acute CD. We searched for publications from 1968 to 31 January 2018. We included studies and unpublished data from government sources that reported patients with acute orally-transmitted CD. We identified 41 papers and we added 932 unpublished cases. In all, our study covered 2470 cases and occurrence of 97 deaths. Our meta-analysis estimated that the case-fatality rate was 1.0% (95% CI 0.0-4.0%). Lethality rates have declined over time (P = .02). In conclusion, orally-transmitted acute CD has considerable lethality in the first year after infection. The lethality in symptomatic cases is similar to that from other routes of infection. The lethality rate of orally-acquired disease has declined over the years.


Asunto(s)
Enfermedad de Chagas , Enfermedad de Chagas/epidemiología , Humanos , Pronóstico
3.
Mem Inst Oswaldo Cruz ; 115: e190364, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32130371

RESUMEN

Oral transmission of Chagas disease has been increasing in Latin American countries. The present study aimed to investigate changes in hepatic function, coagulation factor levels and parasite load in human acute Chagas disease (ACD) secondary to oral Trypanosoma cruzi transmission. Clinical and epidemiological findings of 102 infected individuals attended in the State of Pará from October 2013 to February 2016 were included. The most common symptoms were fever (98%), asthenia (83.3%), face and limb edema (80.4%), headache (74.5%) and myalgia (72.5%). The hepatic enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of 30 ACD patients were higher compared with controls, and this increase was independent of the treatment with benznidazole. Moreover, ACD individuals had higher plasma levels of activated protein C and lower levels of factor VII of the coagulation cascade. Patients with the highest parasite load had also the most increased transaminase levels. Also, ALT and AST were associated moderately (r = 0.429) and strongly (r = 0.595) with parasite load respectively. In conclusion, the present study raises the possibility that a disturbance in coagulation and hepatic function may be linked to human ACD.


Asunto(s)
Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Enfermedad de Chagas/fisiopatología , Factor VIIa/análisis , Hígado/fisiopatología , Proteína C/análisis , Enfermedad Aguda , Adulto , Biomarcadores/sangre , Brasil/epidemiología , Estudios de Casos y Controles , Enfermedad de Chagas/sangre , Enfermedad de Chagas/enzimología , Enfermedad de Chagas/transmisión , Femenino , Humanos , Hígado/enzimología , Masculino , Persona de Mediana Edad , Carga de Parásitos , Estudios Prospectivos
4.
PLoS Negl Trop Dis ; 18(9): e0012407, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-39236037

RESUMEN

BACKGROUND: Maternal-foetal transmission of Chagas disease (CD) affects newborns worldwide. Although Benznidazole and Nifurtimox therapies are the standard treatments, their use during pregnancy is contra-indicated. The effectiveness of trypanocidal medications in preventing congenital Chagas Disease (cCD) in the offsprings of women diagnosed with CD was highly suggested by other studies. METHODS: We performed a systematic review and meta-analysis of studies evaluating the effectiveness of treatment for CD in women of childbearing age and reporting frequencies of cCD in their children. PubMed, Scopus, Web of Science, Cochrane Library, and LILACS databases were systematically searched. Statistical analysis was performed using Rstudio 4.2 using DerSimonian and Laird random-effects models. Heterogeneity was examined with the Cochran Q test and I2 statistics. A p-value of <0.05 was considered statistically significant. RESULTS: Six studies were included, comprising 744 children, of whom 286 (38.4%) were born from women previously treated with Benznidazole or Nifurtimox, trypanocidal agents. The primary outcome of the proportion of children who were seropositive for cCD, confirmed by serology, was signigicantly lower among women who were previously treated with no congenital transmission registered (OR 0.05; 95% Cl 0.01-0.27; p = 0.000432; I2 = 0%). In women previously treated with trypanocidal drugs, the pooled prevalence of cCD was 0.0% (95% Cl 0-0.91%; I2 = 0%), our meta-analysis confirms the excellent effectiveness of this treatment. The prevalence of adverse events in women previously treated with antitrypanocidal therapies was 14.01% (95% CI 1.87-26.14%; I2 = 80%), Benznidazole had a higher incidence of side effects than Nifurtimox (76% vs 24%). CONCLUSION: The use of trypanocidal therapy in women at reproductive age with CD is an effective strategy for the prevention of cCD, with a complete elimination of congenital transmission of Trypanosoma cruzi in treated vs untreated infected women.


Asunto(s)
Enfermedad de Chagas , Transmisión Vertical de Enfermedad Infecciosa , Nifurtimox , Nitroimidazoles , Tripanocidas , Humanos , Femenino , Tripanocidas/uso terapéutico , Tripanocidas/efectos adversos , Enfermedad de Chagas/tratamiento farmacológico , Enfermedad de Chagas/prevención & control , Enfermedad de Chagas/congénito , Enfermedad de Chagas/transmisión , Embarazo , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Nifurtimox/uso terapéutico , Nifurtimox/efectos adversos , Nitroimidazoles/uso terapéutico , Nitroimidazoles/efectos adversos , Estudios Observacionales como Asunto , Recién Nacido , Adulto , Trypanosoma cruzi/efectos de los fármacos , Complicaciones Parasitarias del Embarazo/prevención & control , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico
5.
Cancers (Basel) ; 15(21)2023 Oct 29.
Artículo en Inglés | MEDLINE | ID: mdl-37958380

RESUMEN

Cancer is the abnormal proliferation of physiologically inadequate cells. Studies have identified the cardiac pacemaker pocket as a site of rare neoplasms. To evaluate the clinical outcomes, treatment, prognosis, and individualized management of tumors originating in the cardiac pacemaker pocket, a systematic review was conducted using case reports and case series available in the PubMed/Medline, Science Direct, Cochrane Central, LILACS, and Scientific Electronic Library Online (Scielo) databases. Pacemaker pocket tumors affected patients with a mean age of 72.9 years, with a higher incidence in males (76.9%, n = 10). The average time for neoplasm development was 4.4 years (54.07 months). The most prevalent model was Medtronic (38.4%, n = 5), with titanium (83.3%) being the most common metal composition. Chemotherapy was the most performed procedure among patients (38.4%), followed by radiation therapy (38.4%) and surgical tumor resection (30.7%). Six analyzed cases (46.1%) resulted in death, and four patients (30.7%) achieved a cure. Patients with pacemakers should be routinely evaluated for the occurrence of malignant tumors at the site of device implantation.

6.
Arq Bras Cardiol ; 120(9): e20230050, 2023.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-37820172

RESUMEN

BACKGROUND: Weight gain can trigger mechanisms that increase blood pressure. Nevertheless, obesity causes structural changes in the myocardium, including increased ventricular mass, atrial dilatation, and diastolic and systolic dysfunction. Additionally, blood pressure variations, like morning surge (MS) in obese hypertensive patients may have clinical relevance in cardiovascular events. Although morning blood pressure surge is a physiological phenomenon, excess MS can be considered an independent risk factor for cardiovascular events. OBJECTIVE: To evaluate MS values and their association with left ventricular hypertrophy (LVH) and nocturnal dipping (ND) in obese and non-obese hypertensive patients. METHODS: A cross-sectional study that evaluated BP measurements by ambulatory blood pressure monitoring (ABPM) and the presence of LVH by echocardiography in 203 hypertensive outpatients, divided into two groups: 109 non-obese and 94 obese hypertensives patients. The significance level was set at 0.05 in two-tailed tests. RESULTS: A MS above 20 mmHg by ABPM was detected in 59.2% of patients in the non-obese group and 40.6% in the obese group. LVH was found in 18.1% and 39.3% of patients in the non-obese and obese groups, respectively, p<0.001. In the "obese group", it was observed that a MS>16 mmHg was associated with LVH, [prevalence ratio: 2.80; 95%CI (1.12-6.98), p=0.03]. For the non-obese group, the cut-off point of MS for this association was >22 mmHg. CONCLUSION: High MS was positively associated with LVH, with a particular behavior in the hypertensive obese group.


Asunto(s)
Monitoreo Ambulatorio de la Presión Arterial , Hipertensión , Humanos , Hipertrofia Ventricular Izquierda/diagnóstico por imagen , Hipertrofia Ventricular Izquierda/etiología , Estudios Transversales , Hipertensión/complicaciones , Presión Sanguínea/fisiología , Obesidad/complicaciones
7.
Arq Bras Cardiol ; 114(4): 711-715, 2020 04.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-32491012

RESUMEN

Background The involvement of the autonomic nervous system is one of the mechanisms proposed to explain the progression of myocardial lesion in Chagas disease. Evidences have shown changes in sympathetic and parasympathetic nervous system since the acute phase of the disease, and studies to clarify the pathophysiological and prognostic value of these changes are needed. Objetives To assess blood pressure profile by ambulatory blood pressure monitoring (ABPM) in normotensive patients with acute Chagas disease (ACD) without apparent cardiac damage, and the influence of the infection on nocturnal blood pressure fall. Methods ABPM was performed with 54 patients with ACD and a control group composed of 54 age- and sex-matched normotensive individuals. The alpha level of significance (type I error rate) was set at 5%. Results In the total of 54 patients, 74.0% did not show nocturnal fall in systolic blood pressure, 53.7% did not show nocturnal fall in diastolic blood pressure, and lack of both nocturnal fall in SBP and DBP was observed in 51.8% (*p<0.05). In 12.9% of patients, there was an increase in SBP and in 18.5% increase in DBP (p<0.05). Conclusions In patients with acute Chagas disease, a significant absence of the physiological fall in both systolic and diastolic blood pressure was observed during sleep, and some of the patients showed nocturnal increase in these parameters. These findings suggest autonomic changes in the acute phase of Chagas disease. (Arq Bras Cardiol. 2020; 114(4):711-715).


Asunto(s)
Enfermedad de Chagas , Presión Sanguínea , Determinación de la Presión Sanguínea , Monitoreo Ambulatorio de la Presión Arterial , Ritmo Circadiano , Humanos , Hipertensión
8.
Arq. bras. cardiol ; Arq. bras. cardiol;121(9 supl.1): 279-279, set.2024. tab
Artículo en Inglés | CONASS, SES-SP, SES SP - Instituto Dante Pazzanese de Cardiologia, SES-SP | ID: biblio-1568600

RESUMEN

Breast Cancer (BC) is one of the most common cancers diagnosed in population femmale and it has several subtypes, one of them being theexpressing human epidermal growth factor receptor 2 positive (HER2 +), one of the treatments for HER2+ breast cancer consists of chemotherapy plus trastuzumab deruxtecan. Several clinical trials have shown the effectiveness and safety of trastuzumabe deruxtecano in cancer patients, however, several Adverse Events (AEs) have been described and the decrease in left ventricular ejection has been singled out for more prominent analysis. Objective: We conducted a systematic review and meta-analysis to investigate the cardiovascular effects of Trastuzumab Deruxtecano and whether it can influence the appearance of reduced left ventricular ejection fraction.. METHODS: We performed a systematic search in Embase, PubMed and Cochrane databases for randomized controlled trials (RCTs) showed a decrease in left ventricular ejection fraction in patients using trastuzumab deruxtecan against Her-2-positive breast cancer compared to patients to used another's treatments against this disease. Mean difference (MD) with 95% confidence intervals (CI) were calculated using a random effects model. The heterogeneity was examined in the I2 statistic. P-values > 0.05 were considered statistically significant. The statistical analysis was carried out using R software version 4.2.3. RESULTS: A total of 3 RCTs were included, with a total of 1656 patients evaluated, 928 patients randomized to the use of Trastuzumab Deruxtecan and 728 patients to the use of other treatments according to medical choice, follow-up ranged from 10 to 38 months. There was a visible in the decrease in left ventricular ejection fraction, with a higher incidence in the group that used trastuzumab compared to the placebo group (RR: 5.73%; 95% CI 1.51 - 21.78; I2 33% ; P= 0.010466). Another important point is the discontinuation of treatment due to grade 2 adverse events, classified as reduced LVEF, where a higher incidence is seen in the group that used Trastuzumab Deruxtecan compared to the placebo group (RR 2.11%; 95% CI 1.54 - 2.89; P = 0.000003),7. CONCLUSION: In this meta-analysis, Trastuzumab Deruxtecan showed a relationship with a decrease in left ventricular ejection fraction, displaying the need for more studies to evaluate the cardiotoxicity of trastuzumab and its effects as a whole on the cardiovascular system.


Asunto(s)
Terapéutica , Neoplasias de la Mama , Enfermedades Cardiovasculares , Quimioterapia , Cardiotoxicidad , Trastuzumab , Interpretación Estadística de Datos , Receptores ErbB
9.
Rev Bras Enferm ; 71(suppl 4): 1596-1603, 2018.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-30088629

RESUMEN

OBJECTIVE: to analyze the perceptions of professors and students on academic tutoring. METHOD: descriptive study with a qualitative approach, carried out at the Magalhães Barata School of Nursing, State University of Pará, Brazil. Twenty-seven professors and 32 students participated in the study. Data were collected through semi-structured and individual interviews, using different scripts for professors and students. For analysis, the technique of content analysis was used. RESULTS: we defined three thematic categories: academic tutoring as a tool for strengthening teaching-learning; academic tutoring as a possibility of intellectual and social transformation; and reflections of academic tutoring in nurses' training. FINAL CONSIDERATIONS: the teaching-learning process is referred to as a process in which there must be dialogue, and in which professors, students, and tutors learn with each other, breaking the traditional paradigms of unilateral and vertical transfer of content. Academic tutoring stands out as promoter and strengthener of this process.


Asunto(s)
Bachillerato en Enfermería/métodos , Aprendizaje , Tutoría/normas , Adulto , Anciano , Brasil , Docentes de Enfermería/psicología , Docentes de Enfermería/estadística & datos numéricos , Femenino , Humanos , Masculino , Tutoría/métodos , Persona de Mediana Edad , Investigación Cualitativa , Estudiantes de Enfermería/psicología , Estudiantes de Enfermería/estadística & datos numéricos
10.
Nursing (Ed. bras., Impr.) ; 26(304): 9932-9937, set.2023. tab
Artículo en Inglés, Portugués | LILACS, BDENF - enfermagem (Brasil) | ID: biblio-1525893

RESUMEN

Objetivos: Validação de uma caderneta de saúde para o paciente hipertenso. Metodologia: estudo observacional, analítico e transversal, com posterior produção da caderneta. A coleta foi realizada de março a maio de 2022, após aceite do Comitê de Ética em Pesquisa. Foram incluídos 205 indivíduos com diagnóstico de hipertensão arterial sistêmica acompanhados na Fundação Hospital de Clínicas Gaspar Vianna do Pará, após o diagnóstico de síndrome coronariana aguda. A Validação da Caderneta ocorreu por meio da escala Likert. Resultados: O uso prévio de drogas anti-hipertensivas demonstrou-se significante (89,8%), sendo que 63,9% utilizavam apenas um medicamento, destacando o bloqueador dos receptores de angiotensiva (BRA) de uso predominante (69,6%). Quanto a validação da caderneta junto aos especialistas, com validez completa, obtendo um IVC (Índice de Validade de Conteúdo) acima de 95%. Conclusão: A utilização desta tecnologia educacional facilita o processo de aquisição de conhecimento técnico científica para melhoria assistencial do paciente hipertenso.(AU)


Objectives: Validation of a health booklet for hypertensive patients. Methodology: observational, analytical and cross-sectional study, with subsequent production of the booklet. Data were collected from March to May 2022, after acceptance by the Research Ethics Committee. We included 205 individuals with a diagnosis of systemic arterial hypertension followed at the Fundação Hospital de Clínicas Gaspar Vianna do Pará, after the diagnosis of acute coronary syndrome. The Validation of the Booklet occurred through the Likert scale. Resultados: The previous use of antihypertensive drugs was significant (89.8%), and 63.9% used only one drug, highlighting the angiotensive receptor blocker (ARB) of predominant use (69.6%). As for the validation of the booklet with the specialists, with complete validity, obtaining a CVI (Content Validity Index) above 95%. Conclusion: The use of this educational technology facilitates the process of acquiring scientific technical knowledge to improve the care of hypertensive patients.(AU)


Objetivos: Validación de un folleto de salud para pacientes hipertensos. Metodología: estudio observacional, analítico y transversal, con posterior producción del folleto. Los datos fueron recolectados de marzo a mayo de 2022, después de la aceptación por el Comité de Ética en Investigación. Se incluyeron 205 individuos con diagnóstico de hipertensión arterial sistémica seguidos en la Fundação Hospital de Clínicas Gaspar Vianna do Pará, después del diagnóstico de síndrome coronario agudo. La Validación del Folleto ocurrió a través de la escala Likert. Resultados: El uso previo de antihipertensivos fue significativo (89,8%), y 63,9% utilizaron un solo fármaco, destacando el bloqueador de los receptores angiotensores (BRA) de uso predominante (69,6%). En cuanto a la validación del folleto con los especialistas, con validez completa, obteniendo un CVI (Content Validity Index) superior al 95%. Conclusión: El uso de esta tecnología educativa facilita el proceso de adquisición de conocimientos técnicos científicos para mejorar la atención de los pacientes hipertensos.(AU)


Asunto(s)
Adulto , Persona de Mediana Edad , Cardiología , Tecnología Educacional , Estudio de Validación , Hipertensión
11.
Int. j. cardiovasc. sci. (Impr.) ; 36: e20220035, 2023. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1421768

RESUMEN

Abstract Background Recent reports in the literature have indicated that infection by coronavirus disease 2019 (COVID-19) causes cardiac complications, such as heart failure, arrhythmia, myocardial infarction, and even fulminant myocarditis. These complications have been identified as the cause of death in some patients infected with SARS-CoV-2. Objectives To analyze echocardiographic and electrocardiographic changes, treatments used, and clinical outcomes in patients with myocarditis and COVID-19. Methods The items described for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) were followed. This review included articles in English, Portuguese, and Spanish that reported cardiac involvement, injury, or myocardial inflammation in patients who acquired COVID-19 (SARS-CoV-2). Results Five databases were consulted to find 1,726 articles. After applying the eligibility criteria, a total of 22 studies were considered qualified. ST-segment (section of the electrocardiogram corresponding the end of the S wave to the beginning of the T wave) elevation and tachyarrhythmia were the most common changes found in the electrocardiographic analysis of patients affected with COVID-19. Concerning echocardiography, there was a high frequency of decreased ejection fraction and occurrence of pericardial effusion. Conclusion This systematic review provides a potential tool for the analysis of cardiac changes and implications caused in patients affected by SARS-CoV-2 infection, with emphasis on the presence of tachyarrhythmia on electrocardiogram (ECG) and decreased ejection fraction on echocardiogram.

12.
Arq. bras. cardiol ; Arq. bras. cardiol;120(9): e20230050, 2023. tab, graf
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1513635

RESUMEN

Resumo Fundamento O aumento do peso frequentemente desencadeia mecanismos que elevam a pressão arterial. A obesidade causa mudanças estruturais no miocárdio, incluindo aumento da massa ventricular, dilatação atrial, bem como disfunções diastólicas e sistólicas. Além disso, variações pressóricas nos hipertensos obesos, como a ascensão matinal (AM), podem ter relevância clínica na prevenção dos eventos cardiovasculares. A AM da pressão arterial é um fenômeno fisiológico, que quando elevada pode ser considerada um fator de risco independente para eventos cardiovasculares. Objetivo Avaliar valores da elevação da AM e sua associação com a hipertrofia ventricular esquerda (HVE) e com o Descenso do Sono (DS) em obesos e não obesos hipertensos. Métodos Estudo transversal que avaliou medidas pressóricas à monitorização ambulatorial da pressão arterial (MAPA) e a presença de HVE, avaliada pela ecocardiografia, em 203 pacientes hipertensos em tratamento ambulatorial, separados em dois grupos: 109 não obesos e 94 hipertensos obesos. O nível de significância adotado foi de 0,05 em testes bicaudais. Resultados A AM acima de 20 mmHg à MAPA foi detectada em 59,2% dos pacientes do grupo "não obesos" e em 40,6% no grupo "obesos". A HVE foi encontrada em 18,1% no grupo dos não-obesos e em 39,3% no grupo de obesos, p<0,001. No grupo "obesos" foi observado que AM >16 mmHg esteve associada à HVE, com [razão de prevalência: 2,80; IC95% (1,12-6,98), p=0,03]. Para o grupo dos "não obesos", o ponto de corte da AM para essa associação foi >22 mmHg. Conclusão A AM elevada associou-se positivamente com HVE, com comportamento peculiar na população de hipertensos e obesos.


Abstract Background Weight gain can trigger mechanisms that increase blood pressure. Nevertheless, obesity causes structural changes in the myocardium, including increased ventricular mass, atrial dilatation, and diastolic and systolic dysfunction. Additionally, blood pressure variations, like morning surge (MS) in obese hypertensive patients may have clinical relevance in cardiovascular events. Although morning blood pressure surge is a physiological phenomenon, excess MS can be considered an independent risk factor for cardiovascular events. Objective To evaluate MS values and their association with left ventricular hypertrophy (LVH) and nocturnal dipping (ND) in obese and non-obese hypertensive patients. Methods A cross-sectional study that evaluated BP measurements by ambulatory blood pressure monitoring (ABPM) and the presence of LVH by echocardiography in 203 hypertensive outpatients, divided into two groups: 109 non-obese and 94 obese hypertensives patients. The significance level was set at 0.05 in two-tailed tests. Results A MS above 20 mmHg by ABPM was detected in 59.2% of patients in the non-obese group and 40.6% in the obese group. LVH was found in 18.1% and 39.3% of patients in the non-obese and obese groups, respectively, p<0.001. In the "obese group", it was observed that a MS>16 mmHg was associated with LVH, [prevalence ratio: 2.80; 95%CI (1.12-6.98), p=0.03]. For the non-obese group, the cut-off point of MS for this association was >22 mmHg. Conclusion High MS was positively associated with LVH, with a particular behavior in the hypertensive obese group.

13.
Arq Bras Cardiol ; 120(6): e20230269, 2023 06 26.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-37377258
14.
J Electrocardiol ; 40(1): 47-52, 2007 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-17027018

RESUMEN

BACKGROUND: Hypothermia is defined as a condition in which core temperature (rectal, esophageal, or tympanic) reaches values below 35 degrees C. This may be accidental, metabolic, or therapeutic. The accidental form is frequent in cold-climate countries and rare in those with tropical or subtropical climate. The aim of this study was to evaluate electrocardiographic changes of patients with accidental hypothermia. METHODS: In 59 patients with hypothermia, the following electrocardiogram parameters were analyzed: rhythm and heart rate (HR), P-wave characteristics, PR-interval duration, QRS-complex duration, presence of J wave and its location characteristics, polarity, voltage, aspect and its correlation with the degree of hypothermia, changes in T wave regarding its polarity and characteristics, duration of the QT interval corrected for HR using both Bazett and Friderica formulas, and possible presence of both supraventricular and ventricular arrhythmias were independently and blindly analyzed in the tracings by experienced cardiologists. RESULTS: In 6 patients, electrocardiogram was normal. Sinus bradycardia was observed in 52.5% of the patients. J wave was present in 51 patients, and its voltage correlated inversely and was statistically significantly with the core temperature. Changes in T wave were observed in 47.4% of the cases. QT interval, adjusted for HR, was prolonged in 72.8% of the cases. Idioventricular rhythm was found in 6 cases, total atrioventricular block in 3 cases, and junctional rhythm and atrial fibrillation in 2 patients. CONCLUSIONS: Electrocardiogram changes in accidental hypothermia are frequent and characteristic for this entity improving diagnosis in usually unconscious patients, and in many cases, it may be the diagnostic clue in patients with conscience deficit in emergency units, even in patients from a tropical climate where the population at risk may be exposed to temperatures below 20 degrees C.


Asunto(s)
Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatología , Electrocardiografía/métodos , Frecuencia Cardíaca , Hipotermia/diagnóstico , Hipotermia/fisiopatología , Clima Tropical/efectos adversos , Adulto , Anciano , Arritmias Cardíacas/etiología , Ciudades , Cuidados Críticos/métodos , Femenino , Humanos , Hipotermia/complicaciones , Masculino , Persona de Mediana Edad , Medición de Riesgo/métodos , Factores de Riesgo
15.
Arq Bras Cardiol ; 108(1): 47-52, 2017 Jan.
Artículo en Portugués, Inglés | MEDLINE | ID: mdl-27992034

RESUMEN

BACKGROUND: Left ventricular hypertrophy (LVH) is an important risk factor for cardiovascular events, and its detection usually begins with an electrocardiogram (ECG). OBJECTIVE: To evaluate the impact of complete left bundle branch block (CLBBB) in hypertensive patients in the diagnostic performance of LVH by ECG. METHODS: A total of 2,240 hypertensive patients were studied. All of them were submitted to an ECG and an echocardiogram (ECHO). We evaluated the most frequently used electrocardiographic criteria for LVH diagnosis: Cornell voltage, Cornell voltage product, Sokolow-Lyon voltage, Sokolow-Lyon product, RaVL, RaVL+SV3, RV6/RV5 ratio, strain pattern, left atrial enlargement, and QT interval. LVH identification pattern was the left ventricular mass index (LVMI) obtained by ECHO in all participants. RESULTS: Mean age was 11.3 years ± 58.7 years, 684 (30.5%) were male and 1,556 (69.5%) were female. In patients without CLBBB, ECG sensitivity to the presence of LVH varied between 7.6 and 40.9%, and specificity varied between 70.2% and 99.2%. In participants with CLBBB, sensitivity to LVH varied between 11.9 and 95.2%, and specificity between 6.6 and 96.6%. Among the criteria with the best performance for LVH with CLBBB, Sokolow-Lyon, for a voltage of ≥ 3,0mV, stood out with a sensitivity of 22.2% (CI 95% 15.8 - 30.8) and specificity of 88.3% (CI 95% 77.8 - 94.2). CONCLUSION: In hypertensive patients with CLBBB, the most often used criteria for the detection of LVH with ECG showed significant decrease in performance with regards to sensitivity and specificity. In this scenario, Sokolow-Lyon criteria with voltage ≥3,0mV presented the best performance.


Asunto(s)
Bloqueo de Rama/fisiopatología , Electrocardiografía/métodos , Hipertensión/fisiopatología , Hipertrofia Ventricular Izquierda/diagnóstico , Hipertrofia Ventricular Izquierda/fisiopatología , Anciano , Bloqueo de Rama/diagnóstico , Ecocardiografía , Femenino , Humanos , Hipertensión/diagnóstico , Masculino , Persona de Mediana Edad , Factores de Riesgo , Sensibilidad y Especificidad , Factores de Tiempo
16.
Mem. Inst. Oswaldo Cruz ; 117: e210172, 2022. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1386363

RESUMEN

In this chapter, the main prognostic markers of Chagas heart disease are addressed, with an emphasis on the most recent findings and questions, establishing the basis for a broad discussion of recommendations and new approaches to managing Chagas cardiopathy. The main biological and genetic markers and the contribution of the electrocardiogram, echocardiogram and cardiac magnetic resonance are presented. We also discuss the most recent therapeutic proposals for heart failure, thromboembolism and arrhythmias, as well as current experience in heart transplantation in patients suffering from severe Chagas cardiomyopathy. The clinical and epidemiological challenges introduced by acute Chagas disease due to oral contamination are discussed. In addition, we highlight the importance of ageing and comorbidities in influencing the outcome of chronic Chagas heart disease. Finally, we discuss the importance of public policies, the vital role of funding agencies, universities, the scientific community and health professionals, and the application of new technologies in finding solutions for better management of Chagas heart disease.

17.
Rev. bras. hipertens ; 28(1): 14-19, 10 març. 2021.
Artículo en Portugués | LILACS | ID: biblio-1367789

RESUMEN

A hipertensão arterial resistente (HAR) é definida quando, apesar do tratamento com pelo menos três medicações anti- -hipertensivas (incluindo um diurético) de diferentes classes a meta pressórica não é alcançada. Nesta sequência de fármacos, por muitos anos se utilizou empiricamente ou baseado em pequenos estudos, a espironolactona. Os estudos Pathway 2 e 3 vieram para corroborar a importância deste quarto fármaco, a espironolactona, como o mais eficaz em termos de potencia anti-hipertensiva, como também explicar os aspectos fisiopatológicos que levam o hipertenso a ficar resistente. Nesta revisão e análise crítica dos fármacos anti-hipertensivos na HAR destacamos os principais mecanismos envolvidos no não controle da pressão e as estratégias para um melhor controle pressórico


Resistant arterial hypertension (RAH) is defined when, despite treatment with at least three antihypertensive medications (including a diuretic) of different classes, the pressure target is not achieved. In this sequence of drugs, for many years it was used empirically or based on small studies, spironolactone. Pathway 2 and 3 studies have come to corroborate the importance of this fourth drug, spironolactone, as the most effective in terms of antihypertensive potency, as well explain the pathophysiological aspects that lead hypertensive patients to become resistant. In this review and critical analysis of antihypertensive drugs in hypertension, we highlight the main mechanisms involved in the lack of pressure control and the strategies for better pressure control


Asunto(s)
Espironolactona/uso terapéutico , Amilorida/uso terapéutico , Hipertensión/tratamiento farmacológico
18.
Rev Bras Hiperten ; 28(3): 238-242, 20210910.
Artículo en Portugués | LILACS-Express | LILACS | ID: biblio-1367761

RESUMEN

A pré-eclâmpsia (PE) caracteriza-se por um quadro clínico grave e multissistêmico em gestantes previamente normotensas e até o momento sem etiologia completamente esclarecida. Vários mecanismos fisiopatológicos têm sido implicados na patogênese e biomarcadores vêm sendo estudados para rastreamento de PE, porém ainda precisam ser validados para detecção precoce deste estado hipertensivo, o que complica a previsão e o tratamento da PE


Pre-eclampsia (PE) is a severe and multisystemic in previously normotensive pregnant women and, so far without fully clarified etiology. Several pathophysiological mechanisms have been implicated in the pathogenesis and biomarkers have been studied for PE screening, but they still need to be validated for early detection of this hypertensive state which complicates PE prediction and treatment.

19.
Rev. bras. hipertens ; 28(1): 20-26, 10 març. 2021.
Artículo en Portugués | LILACS | ID: biblio-1367793

RESUMEN

A interação dos bloqueadores do sistema renina angiotensina com o SARS-CoV-2 permanece obscura. Os inibidores do sistema renina angiotensina aldosterona (IECAs) e os bloqueadores do receptor AT1 da angiotensina 2 (BRAs) são fármacos com evidências robustas para terapia farmacológica de pacientes portadores, principalmente de hipertensão arterial e insuficiência cardíaca, além de outras comorbidades cardiovasculares. Os pacientes que se beneficiam desta terapêutica são considerados grupos de risco para má evolução desta virose e não há na literatura um consenso a respeito desta questão, em vista do vírus utilizar a expressão da ECA2 para penetração no ser humano. Apesar destas considerações fisiopatológicas da biologia do vírus, as principais diretrizes recomendam não suspender a terapia dos pacientes em uso dos bloqueadores do sistema renina angiotensina aldosterona no curso da infecção com o COVID-19. Aditivamente, o estudo BRACE-CORONA trouxe evidências mais consistentes para não suspensão desses fármacos


The interaction of blockers of the renin angiotensin system with SARS-COV-2 remains unclear. Inhibitors of the renin angiotensin aldosterone system (ACE inhibitors) and angiotensin 2 AT1 receptor blockers (BRAs) are drugs with robust evidence for pharmacological therapy for patients with mainly arterial hypertension and heart failure, and other cardiovascular comorbidities. Patients who benefit from this therapy are considered groups at risk for poor evolution of this virus and the literature still does not have a consensus on this issue, in view of the virus using the expression of ECA2 to penetrate in humans. Despite these athophysiological considerations of the biology of the virus, the main guidelines recommend not to suspend therapy for patients using blockers of the renin angiotensin aldosterone system in the course of infection with COVID-19. In addition, the BRACE corona study has more consistent evidence for not suspending these drugs.


Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Interacciones Farmacológicas , COVID-19/tratamiento farmacológico , Hipertensión/tratamiento farmacológico
20.
Arq Bras Cardiol ; 116(3): 516-658, 2021 03.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-33909761
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA